Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > New Chemical Entities, Drug Leads

Categories

[Search within category]

A High Potency CYP3A4 Inhibitor for Pharmacoenhancement of Drugs

      CYP3A4 is the most clinically relevant drug metabolizing enzyme in the body, as it is responsible for the oxidation and breakdown of ~60% of current drugs on the market.  Researchers at UCI have developed novel CYP3A4 inhibitors, that are highly potent and more specific, exhibit fewer side effects, and are both cheaper, and easier to-synthesize than current commercially available CYP3A4 inhibitors. 

Novel Synthesis of Streptogramin A Antibiotics

A modular, scalable, chemical synthesis platform that produces new Streptogramin A class antibiotic candidates.

A Novel Mixture for Intravenous Sedation

UCLA researchers from the Department of Anesthesiology and Perioperative Medicine have developed a novel anesthetic mixture which combines anxielytic, narcotic, and sedation effects in a safe, effective solution.

Novel Non-Peptidomimetic Prenyltransferase Inhibitors

UCLA Researchers in the Department of Chemistry & Biochemistry and School of Medicine have synthesized a series of small molecule therapeutics against GGTase-I and GGTase-II, both of which are critical oncology drug targets.

Antibody-Interferon Fusion Proteins For Enhancing Adoptive T Cell Therapies For The Treatment Of Cancer

UCLA researchers in the Departments of Medicine and Microbiology, Immunology and Molecular Genetics have developed a novel combination therapy for enhanced efficacy of adoptive T cell therapies.

BMP Binding Proteins and Prosthetic Surfaces

UCLA researchers have developed a method to attach and enhance the activity of bone growth factors to prostheses through BMP binding proteins to increase the integration of prostheses and bone.

BBP as a Complexed Carrier for Bone Growth Factors

UCLA researchers have identified a BMP binding peptide that binds to bone growth factors to increase their residence time at the site of implantation for treatment of bone defects.

Use of Il-10 Inhibitors as Adjuvants for Vaccination or Immunotherapy

Researchers at the University of California, Davis have developed a process of administering inhibitors of Interleukin 10 (IL-10) signaling concomitantly with a vaccine or other immunostimulus, so that responses to vaccination occur in the absence of such signaling.

Nanoparticulate Mineralized Collagen Glycosaminoglycan Scaffold With An Anti-Resorption Factor

Researchers in the Division of Plastic and Reconstructive Surgery at the UCLA David Geffen School of Medicine and the Institute of Genomic Biology at the University of Illinois Urbana Champaign (UIUC) have developed novel methods to incorporate anti-resorption factor into nanoparticulate mineralized collagen glycosaminoglycan scaffold to maximize bone regeneration.

Allosteric BACE Inhibitors For Treatment Of Alzheimer’s Disease

UCLA researchers from the Department of Neurology have discovered a new class of drug candidates for Alzheimer’s disease. These small molecule compounds can specifically inhibit target enzymes to prevent target protein cleavage through an allosteric mechanism, preventing off-target side effect.

Humanized Antibodies to the Extracellular Domains of Human N-Cadherin

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed humanized antibody therapies for invasive prostate and bladder cancers that express N-cadherin.

Antibody Selection to Prevent or Treat Alzheimer’s Disease

Therapeutic antibodies have been developed to prevent or slow the cognitive decline in Alzheimer’s disease (AD) but with limited clinical success to date. These treatment failures suggest that antibodies vary in their therapeutic efficacy and that more effective antibodies or combinations of antibodies need to be identified. To address this issue, researchers at UCI have developed a novel screening platform that can identify antibodies that may prevent or treat AD or other neurodegenerative disorders with high efficacy from human blood.

Bioavailable Dual sEH/PDE4 Inhibitor for Inflammatory Pain

Researchers at the University of California, Davis, have developed a dual soluble epoxide hydrolase (sEH)/ phosphodiesterase 4 (PDE4) inhibitor for the treatment of inflammatory pain.

Small Molecule sEH Inhibitors to Treat Alpha-Synuclein Neurodegenerative Disorders

Researchers at the University of California, Davis have developed small molecule inhibitors to prevent or reverse the progression of neurodegenerative diseases or symptoms.

PTUPB Compound Potentiates Cisplatin-Based-First Line Therapies with No Additional Toxicity

Researchers at the University of California, Davis have discovered a compound that inhibits both cyclooxygenase-2 (COX-2) /soluble epoxide hydrolase (sEH) to improve effectiveness of chemotherapy while protecting normal tissue from cisplatin toxicity.

Joint Pharmacophoric Space through Geometric Features

Pharmacophore analysis through examination of Joint Pharmacophore Space of chemical compounds, targets, and chemical/biological properties.

Selective Voltage Gated KV1.3 Potassium Channel Inhibitors

Researchers at the University of California, Davis, have discovered a composition of 5-phenoxyalkoxypsoralens that inhibits potassium channels to treat autoimmune diseases and disorders that involve abnormal homeostasis, body weight and peripheral insulin sensitivity.

Antisense Oligonucleotide Therapy for B Cell Mediated Cancers

Researchers at the University of California, Davis have developed a targeted therapy using an antisense oligonucleotide (ASO) to treat precursor B cell (pre-B) acute lymphoblastic leukemia (ALL).

Novel Therapy for Treating Fungal Infection of the Cornea

Fungal keratitis is an infection of the cornea caused by pathogenic fungi that is challenging to treat. This therapy is a novel topical application of a commercially-available malarial drug to treat fungal keratitis with fewer side effects than current treatments.

Soluble Epoxide Hydrolase-Conditioned Stem Cells for Cardiac Cell-Based Therapy

Researchers at the University of California, Davis, have adapted novel soluble epoxide hydrolase (sEHI) inhibitors as adjuvant treatment in cardiac cell-based therapy to improve the survival and engraftment of stem cells by pre-conditioning with the sEHI in vitro.

Inhibitors Of Zika Virus

UCLA researchers in the Department of Psychiatry and Biobehavioral Sciences, Department of Radiation Oncology and Department of Pathology have identified sulfonamide-based small molecules that show anti-Zika activity at low nanomolar range.

Novel Inhibitor of HIV Replication

UCLA researchers in the David Geffen School of Medicine have discovered a new small molecule inhibitor for HIV-1 replication.

A Highly Error-Prone Orthogonal Replication System For Targeted Continuous Evolution In Vivo

Inventors at UC Irvine have engineered an orthogonal DNA replication system capable of rapid, accelerated continuous evolution. This system enables the directed evolution of specific biomolecules towards user-defined functions and is applicable to problems of protein, enzyme, and metabolic pathway engineering.

Small Molecule Regulators of let-7 MicroRNA Targets in Acute Myeloid Leukemia Cancer Stem Cells

UCLA researchers have identified a class of small molecule phosphodiesterase inhibitors that suppress let-7 target genes and inhibit cell growth in acute myeloid leukemia cancer cell lines.

Antimicrobial, Stimuli-responsive Polysaccharide

State of the art antimicrobial therapeutics, while effective and promising, remain only short-term solutions to the overall challenge of drug-resistant microbes. UCI researchers have developed a chitosan-based nanoantibiotic that is non-toxic and carries potential for broad spectrum use.

  • Go to Page: